These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 23169232

  • 1. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR, Mata M.
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [Abstract] [Full Text] [Related]

  • 2. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ, Kulisevsky J.
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [Abstract] [Full Text] [Related]

  • 3. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

  • 4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
    Giménez de Béjar V, Carballo-Cordero M.
    Rev Neurol; 2012 Nov; 55 Suppl 1():S25-9. PubMed ID: 23169230
    [Abstract] [Full Text] [Related]

  • 6. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
    Müller T.
    Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
    [Abstract] [Full Text] [Related]

  • 7. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V.
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [Abstract] [Full Text] [Related]

  • 8. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W, Stacy M.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [Abstract] [Full Text] [Related]

  • 9. Apomorphine: North American clinical experience.
    Stacy M.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
    [Abstract] [Full Text] [Related]

  • 10. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
    Stefani A, Stanzione P, Bassi A, Mazzone P, Vangelista T, Bernardi G.
    J Neural Transm (Vienna); 1997 Mar 23; 104(8-9):895-904. PubMed ID: 9451721
    [Abstract] [Full Text] [Related]

  • 11. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [Abstract] [Full Text] [Related]

  • 12. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Mar 23; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 13. Use of apomorphine in Parkinson's disease.
    Stocchi F.
    Neurol Sci; 2008 Dec 23; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [Abstract] [Full Text] [Related]

  • 14. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004 Dec 23; 5(4):211-2. PubMed ID: 15230626
    [Abstract] [Full Text] [Related]

  • 15. Practical considerations in the use of apomorphine injectable.
    Bowron A.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
    [Abstract] [Full Text] [Related]

  • 16. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU, Lewitt PA, Fernandez HH.
    Expert Opin Pharmacother; 2007 Nov 23; 8(16):2799-809. PubMed ID: 17956200
    [Abstract] [Full Text] [Related]

  • 17. [Limits of conventional oral and transdermal medication in Parkinson's disease].
    García-Ruiz PJ, Luquin MR.
    Rev Neurol; 2012 Nov 23; 55 Suppl 1():S3-6. PubMed ID: 23169231
    [Abstract] [Full Text] [Related]

  • 18. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May 23; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 19. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M, Silver D.
    Parkinsonism Relat Disord; 2008 May 23; 14(2):85-92. PubMed ID: 18083605
    [Abstract] [Full Text] [Related]

  • 20. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
    Dewey RB, Maraganore DM, Ahlskog JE, Matsumoto JY.
    Clin Neuropharmacol; 1996 Jun 23; 19(3):193-201. PubMed ID: 8726538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.